Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.

about

Health economic analyses of psoriasis management: a systematic literature search.The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis.Adalimumab: A Review in Chronic Plaque Psoriasis.A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.

P2860

Q36082201-4469B767-3182-411B-A202-2FD156411987 Q38612964-C839589A-B199-49F1-87FD-8836AC8A684A Q38639495-83C338B3-D1C1-4AA6-93B6-1C58FF374D7B Q48104953-B8371F7B-B6DE-4024-8B30-B480FAF1AA4C

P2860

Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.

Item

http://www.wikidata.org/entity/Q39070719

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Biological therapies for the t ...... a cost-effectiveness analysis.

@en

Biological therapies for the t ...... a cost-effectiveness analysis.

@nl

type

Item

label

Biological therapies for the t ...... a cost-effectiveness analysis.

@en

Biological therapies for the t ...... a cost-effectiveness analysis.

@nl

prefLabel

Biological therapies for the t ...... a cost-effectiveness analysis.

@en

Biological therapies for the t ...... a cost-effectiveness analysis.

@nl

P1476

Biological therapies for the t ...... a cost-effectiveness analysis

@en

P2093

Eleanor J Samarasekera

http://www.w3.org/2001/XMLSchema#string

Karina Jackson

http://www.w3.org/2001/XMLSchema#string

Laura M Sawyer

http://www.w3.org/2001/XMLSchema#string

Ruth Murphy

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects.

Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Inpatient management of psoriasis: a multicentre service review to establish national admission standards.

Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines.

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.

Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.

A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.

P2888

s40273-014-0226-y

P304

163-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S40273-014-0226-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Catherine H Smith

David Wonderling

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25526841

http://www.w3.org/2001/XMLSchema#string

Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.

about

P2860

P2860

Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698